PT141 CAS 189691-06-3 Growth Hormone Releasing Peptide For Muscle Growth

 
PT141 CAS 189691-06-3 Growth Hormone Releasing Peptide For Muscle Growth Health
 

 
 
PT-141 (Bremelanotide) is the first of a new class of drugs called melanocortin agonists being developed to treat sexual dysfunction. The mechanism of action of PT-141(Bremelanotide) may offer significant safety and efficacy benefits over currently available products because it acts on the pathway that controls sexual function without acting directly on the vascular system.
Clinical data indicates that PT-141(Bremelanotide) may be effective in treating a broad range of patients suffering from ED. The nasal formulation of PT-141(Bremelanotide) being developed is as convenient as oral treatments, is more patient-friendly than invasive treatments for ED, such as injections and trans-urethral pellets, and appears to result in a rapid onset of action.
 
About PT-141Bremelanotide (PT-141) was developed from Melanotan 2 (MT-II). PT-141 is a metabolite of MT-II that lacks the C-terminal amide function-stripping away tanning properties.
Bremelanotide (formerly PT-141) is a compound under drug development by Palatin Technologies as a treatment for female sexual dysfunction, hemorrhagic shock and reperfusion injury. It functions by activating the melanocortin receptors MC1R and MC4R, to modulate inflammation and limiting ischemia.
It was originally tested for intranasal administration in treating female sexual dysfunction but this application was temporarily discontinued in 2008 after concerns were raised over adverse side effects of increased blood pressure. As of March, 2012, Palatin is conducting a human Phase 2B study using a new subcutaneous drug delivery system that appears to have little effect on blood pressure.
PT-141​ Application:
Bremelanotide or PT-141 is the generic term for a new research peptide for use in helping improve sexual dysfunction in men (erectile dysfunction or impotence) as well as helping improve sexual dysfunction in women (sexual arousal disorder). Bremelanotide, PT-141 does not act on the vascular system like the former compounds but it is known and has been shown to help increase sexual activity in both male and female mammals.
Subcutaneous injection of Bremeranotide is under the skin using a single automatic syringe. The automatic syringe has no visible needles. In the Phase 3 clinical trial, women gave the naupivacin - the automatic syringe was the rest by pressing the automatic syringe on the thigh or abdomen.
Women do not have to take daily triclosan. Bremelanotide is required only before expected sexual activity.
In our recently completed Phase 2B clinical trial, 1.25 mg and 1.75 mg doses of bruylamin peptide significantly increased the number of sexual arousal, sexual desire and sexual satisfaction events and reduced the pain associated with premenopausal women with FSD.
Sexually active sexual dysfunction (HSDD) and HSDD combination of female sexual awakening in women were observed efficacy.
The percentage of women receiving 1.75 mg of bromidolide was significantly higher than 55%, clinically significant compared with at least the baseline of sexual events, compared with 37% of women receiving placebo. In addition, a significant increase in the percentage of women compared with placebo also achieved clinically significant improvements in sexual function, as measured by FSFI (53% vs 29%), and clinically relevant for sexual dysfunction The reduction was compared with FSDS-DAO (69% vs 45%).
Benefits:
Bremelanotide (PT-141) was developed from Melanotan 2 (MT-II).PT-141 is a metabolite of MT-II that lacks the C-terminal amide function-stripping away tanning properties.
 
PT-141 is a potential remedy for the treatment of sexual dysfunction; specifically, male erectile dysfunction. Studies have shown that PT-141 does not act on the vascular system like former compounds, but allegedly works by activating melanocortin receptors in the brain, therefore helping increase ones sexual stimulation.
PT-141 is a melanocortin based peptide that has shown effectiveness in clinical studies on both male and female rats. Male rats have shown erectile response with doses as low as 1-2 mgs whereas most female rats have shown positive results with higher doses around 2-3 mgs.
PT-141,Used as an erectile dysfunction solution, it is used by men who want to bring back the fire into their sex life in terms of achieving rock-hard erections that do not only satisfy them but their partners as well. In the process, they never have to take any other medications or choose hormone replacement therapy again with it at their side.
 

Tips:
HOW TO MAKE AN ORDER?
1. Tell us what you need ( use for what/product name & quantity ), you will get an advice and a quotation.
2. Full payment would be done once we come to an agreement on all details .
3. Your goods will be sent out within 24 hours after payment , tracking number available.
4. The goods will reach you in 3~7 days.
 
WHY CHOOSE US?
 
1. High quality: Our factories are professional in raw powder production with experience over 10 years. Having good reputation all over the world, our products have been exported to Germany, Norway, Poland, Finland, Spain, UK, France, Russia, USA, Australia, Japan, Korea and many other countries, over 100kgs each month.
2. Competetive price: All powders are factory directly supplied, it's factory price and negotiable.
3. Fast and safe delivery: Your goods will be sent out within 24 hours after payment, tracking number available, customs pass rate ≥99%.
4. Good pre&after-sales service: Any problem please feel free to contact us, we will always be online for you.
High quality, competetive price, fast and safe delivery, good service,that's us! Welcome to contact!